ERBB2 and neoplasm: Monoclonal antibodies or small molecule anti-tumor agents targeting the critical carcinogenic molecular hubs, such as VEGF, EGFR and HER-2, have earned appreciation in the anti-cancer treatment and have been adopted by the evidence based clinical guidelines.